Trial Profile
A retrospective study assessing safety of immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Anal cancer; B-cell lymphoma; Colon cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Hodgkin's disease; Liver cancer; Lymphoma; Malignant melanoma; Mediastinal disorders; Merkel cell carcinoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- 27 Jul 2021 New trial record